Shots:
- The US FDA has received NDA of icotrokinra for the treatment of pts (≥12yrs.) with mod. to sev. plaque PsO
- NDA was backed by P-III (ICONIC-TOTAL, ICONIC LEAD, ICONIC-ADVANCE 1 & 2) trials, where ICONIC-LEAD (vs PBO) met its co-1EPs of IGA 0/1 & PASI 90 at Wk. 16, plus showed higher rates of clear or almost clear skin at Wk. 16 in pediatric pts
- ICONIC-TOTAL depicted icotrokinra’s potential in difficult-to-treat scalp & genital PsO, while ICONIC-ADVANCE 1 & 2 (vs PBO & Sotyktu) met its co-1EPs (IGA 0/1 & PASI 90) & key 2EPs at Wk. 16 & 24. Long term data incl. 52wk. data from ICONIC-LEAD & ICONIC-TOTAL, plus results from withdrawal analysis to be presented in future
Ref: Johnson & Johnson | Image: Johnson & Johnson | Press Release
Related News:- The US FDA Grants Priority Review to Johnson & Johnson’s TAR-200 for BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
